Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $16 from $23 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Zymeworks appoints Kristin Stafford as CFO
- NovoCure’s EF-32 Optune® Trial Reaches Completion, Setting Up a Key Catalyst for NVCR Investors
- NovoCure Announces Positive Phase 2 PANOVA-4 Pancreatic Cancer Data
- Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint
- Novocure gets reimbursement approval in Japan for Optune Lua